Research programme: PCSK9 protein inhibitors - Serometrix

Drug Profile

Research programme: PCSK9 protein inhibitors - Serometrix

Alternative Names: SX PCK9

Latest Information Update: 16 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Serometrix
  • Class Small molecules
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hypercholesterolaemia

Most Recent Events

  • 16 Mar 2015 PCSK9 protein inhibitors are available for licensing as of 16 Mar 2015. http://www.serometrix.com/partnering.html
  • 16 Mar 2015 Preclinical trials in Hypercholesterolaemia in USA before March 2015 (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top